This article refers to:
Nafee T, Aslam A, Chi G, et al. Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors. Expert Rev Cardiovasc Ther. 2017;15(4):237–245.
http://dx.doi.org/10.1080/14779072.2017.1305889
When the above article was first published online, Table 1 contained an error in the ANNEXA-4 trial entry (third row) in the “Safety Signals” column. This has now been corrected in both the print and online version as described below:
Original online version:
No infusion reactions; 8% thrombotic events 15% mortality at 30 days
Corrected version:
No infusion reactions; 18% thrombotic events 15% mortality at 30 days
Taylor & Francis apologises for this error.